SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of the FDAs November 22 target decision on deramiocel for Duchenne muscular dystrophy, with traders weighing whether the amended application and longer-term upper-limb data could support approval. Bullish speculation has been reinforced by commercial-launch job postings and optimism about FDA flexibility, while skeptics cite prior advisory-panel concerns and caution that hiring does not guarantee approval; INOs separate FDA approval has also provided a sentiment tailwind.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a broad crypto pullback, with traders debating whether concerns over Binances reported security incident and exchange trust are adding pressure or coinciding with an existing market downtrend. Sentiment is split between bearish calls for further weakness and buyers treating the decline as an opportunity to accumulate and stake.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,665,205.855202 with 36,823,860,963.224877 in circulation. The last known price of Cardano is 0.19280151 USD and is up 0.00 over the last 24 hours. It is currently trading on 1752 active market(s) with $154,401,668.14 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs volatile price action and technical levels dominate the discussion, with traders debating whether rebounds and breakout setups can hold or whether further weakness will follow. Sentiment is sharply divided between dip-buying and short-squeeze hopes on one side, and concerns about continued losses and a lack of altcoin momentum on the other.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries, including sharply higher overseas sales, are driving discussion, but traders are debating whether volume growth can translate into better margins and meet the companys Q4 delivery ambitions. The upbeat operating update is being weighed against a steep share-price decline and concerns about China EV competition and profitability.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A modest rebound has prompted pump and short-squeeze chatter around the Trump-themed meme coin, while most discussion focuses on its steep decline and accusations that it is a speculative pump-and-dump. Some holders remain bullish, but skeptics warn of further losses.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical peers, with traders pointing to broader risk-off sentiment and concerns about dilution, valuation, and execution rather than a clear company-specific setback. Bulls are buying the dip on data-center optics demand and upcoming earnings, while skeptics remain wary of further declines.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high ahead of the Q3 report is driving attention, with bullish traders pointing to BRIUMVIs commercial growth and speculating about a short squeeze or buyout. Others caution that the buyout talk is unconfirmed and that the earnings results and upcoming subcutaneous BRIUMVI data will be important tests of the rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Positioning around Luckins scheduled third-quarter earnings report is the main focus, with traders hoping for strong results and a rally while others expect a post-report pullback. The debate is amplified by frustration over the stocks prolonged weak, range-bound trading and speculation about buybacks or a future relisting.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly earnings beat and strong refining results are driving attention, with traders highlighting higher shareholder returns and record-high shares. The reaction is broadly positive, though some caution that the stock looks extended and refining strength may not last if margins normalize.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gileads strong third-quarter results and raised outlook, led by continued HIV drug demand, are driving attention as shares reach fresh highs. Traders are broadly upbeat about the earnings and breakout, though some remain cautious after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add URGN Stock to Your Portfolio Now

UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

UroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics

(RTTNews) - Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics...

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released...

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +26.32% and +16.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today? 

Equity

Investors showed confidence in healthcare improvements, strong biotech patents, and rising packaging demand. 


UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

Key PointsAccording to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds...

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Pharma Ltd

Neutral Sentiment

<ul class="summary-bullets"><li>CVS Health reached a four-year high of $110.62 ahead of Q2 earnings, driven by retail upgrades and new healthcare services.&nbsp;</li><li>UroGen Pharma hit a seven-year high of $43.92 after Guggenheim raised its price target, citing prescription growth and stronger commercial prospects.&nbsp;</li><li>Crown Holdings hit a four-year high of $121.76 after strong Q2 results, driven by higher beverage can demand.&nbsp;</li></ul>CVS Health (CVS), UroGen Pharma (URGN), and Crown Holdings (CCK) stocks climbed to 52-week highs on Tuesday as investors focused on operational improvements, commercial progress, and earnings optimism.CVS Health and Crown Holdings stocks ended the session 2% higher, while UroGen Pharma gained over 6%.&nbsp;<h2 class="st-heading-2">CVS Expands Healthcare Retail Strategy</h2><a href="https://stocktwits.com/symbol/CVS">CVS Health stock</a> reached a four-year high of $110.62 on Tuesday ahead of its fiscal second-quarter (Q2) earnings announcement scheduled for August 5, as the company is working to modernize its retail footprint while developing higher-margin healthcare offerings.According to Fiscal AI data, analysts expect Q2 revenue of $100.7 billion with earnings of $1.84 per share.&nbsp;The company last week introduced its first pharmacy-centered concept store in Houston, reflecting a move toward more efficient layouts designed around patient care. CVS has also entered the pet prescription market by making animal medications available through its pharmacy locations, opening another revenue channel within its retail network.On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘neutral’ territory the previous day.&nbsp;<h2 class="st-heading-2">UroGen Pharma Gains From Patent Protection</h2><a href="https://stocktwits.com/symbol/URGN">UroGen Pharma stock</a> surged to a seven-year high of $43.92 as Guggenheim increased its price target for URGN to $42 from $32 while maintaining a ‘Buy’ rating. The firm pointed to prescription growth, recent business developments, and improving commercial expectations.The company has strengthened its long-term commercial outlook after receiving a U.S. Patent Allowance expected to protect ZUSDURI (FDA-approved, non-surgical treatment for adults with recurring low-grade bladder cancer) and its investigational treatment UGN-103 through July 2044.&nbsp;Retail sentiment around the stock remained in ‘Neutral’ territory.&nbsp;<h2 class="st-heading-2">Crown Holdings Benefits From Beverage Demand</h2><a href="https://stocktwits.com/symbol/CCK">Crown Holdings stock</a> reached a four-year high of $121.76 after a strong Q2 performance, helped by a 5% increase in global beverage can volumes. The company raised its full-year adjusted earnings outlook to $8.30 to $8.50, from its previous forecast of $7.90 to $8.30.Crown also anticipates adjusted free cash flow of at least $900 million. Mizuho lifted its price target on Crown Holdings to $135 from $130 following the results. Retail sentiment around the stock turned to ‘bullish’ from ‘extremely bullish’ territory the previous day.&nbsp;So far this year, CCK and CVS stocks have gained 14% and 31% respectively, while URGN stock has surged 86%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nok-stock-rises-overnight-retail-bulls-charged-after-smci-s-backlog-surge-call-nokia-pillar-of-infrastructure-ahead-of-earnings/cZZmGS6R7w5">NOK Stock Rises Overnight: Retail Bulls Charged After SMCI's Backlog Surge, Call Nokia 'Pillar Of Infrastructure' Ahead Of Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CVS Health managed to beat analyst expectations on earnings but revenue fell short of estimates.

CVS Health (CVS), UroGen Pharma (URGN), and Crown Holdings (CCK) stocks climbed to 52-week highs on Tuesday as investors focused on operational improvements, commercial progress, and earnings optimism.

Crown Holdings, Inc.

CVS Health Corp

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$32.72
Prev Close	$33.48
Open	$33.14
Dividend Yield	0.00%
50-Day Moving Average	$40.44
Beta	1.20
Avg. Volume	745,729.91
PE Ratio	-16.41

52-Week High	$50.81
52-Week Low	$16.50
Market Capitalization	$1.6B
EPS (Annual)	-$3.19
Price to Book	-12.08
Revenue Per Employee	$377,278.35

Feed

News

Sentiment

Earnings

Fundamentals

Info

URGN Fundamentals